Blau Farmacêutica (BLAU3) Q1 2026 earnings summary

Executive summary

• Net revenue reached BRL 435 million in Q1 2026, growing between 17% and 33% year-over-year, with recurring EBITDA margin at 23.9% and recurring net income at BRL 36 million; excluding exchange rate effects, recurring net income was BRL 58 million, up 8% year-over-year.

• Zero leverage maintained, with cash and financial investments exceeding gross debt by BRL 15 million, providing flexibility for investments.

• Growth was driven by strong performance in the hospital segment, federal bidding, and resilient demand for mature products in both public and private channels.

• Launches increased 33% year-over-year, now representing 7% of net revenue, with new product lines expected to contribute more significantly in coming quarters.

• Gross margin expanded to 41.4%, up 130 basis points year-over-year, driven by efficiency gains and favorable currency.

Financial highlights

• Hospital segment revenue grew 18% year-over-year, led by federal bids and mature products.

• Retail and aesthetics segment revenue increased 2% year-over-year, with launches contributing 33% growth.

• Recurring EBITDA reached BRL 104 million, up 25% year-over-year, with margin up 170 bps to 23.9%.

• Working capital cycle impacted by supplier financing and inventory build-up for new lines, expected to normalize during the year.

• Expenses grew in line with revenue, with no dilution in Q1 due to prior investments in teams.

Outlook and guidance

• New production lines and launches, especially monoclonal antibodies, are expected to drive revenue growth throughout 2026, with full effect in 2027.

• Pipeline of drugs in ANVISA queue represents a BRL 2.7 billion addressable market; launches expected to accelerate as approvals come through.

• EBITDA margin expected to improve by 100-200 basis points in 2026 as revenue grows and operational leverage increases.

• Expense dilution and cost optimization anticipated to contribute to margin growth in the second half of the year.

• Investment pace to accelerate, especially in clinical studies and innovation.